Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases

• Published in: Surgery today (Tokyo, Japan) Vol. 32; no. 12; p. 1075
• Main Authors: Shimada, Shinya, Hayashi, Naoko, Marutsuka, Takashi, Baba, Yoshifumi, Yokoyama, Sachio, Iyama, Ken-ichi, Ogawa, Michio
• Format: Journal Article
• Language: English
• Published: Japan 01.01.2002
• Subjects: Aged; alpha-Fetoproteins - analysis; Antineoplastic Agents - administration & dosage; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Combined Chemotherapy Protocols; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Cisplatin - administration & dosage; Humans; Infusions, Intravenous; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Male; Middle Aged; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stomach Neoplasms - secretion; Tomography, X-Ray Computed
• ISSN: 0941-1291
• DOI: 10.1007/s005950200217

Alpha-fetoprotein (AFP)-producing gastric carcinoma generally causes multiple liver metastases and has an extremely poor prognosis. There is no standard chemotherapy for this disease. Two recent consecutive patients who had AFP-producing gastric carcinoma were treated with a novel chemotherapy regimen: irinotecan hydrochloride (100 mg/body over 90 min) plus low-dose cisplatin (10 mg/body) by intravenous infusion. Treatment was done weekly during admission and once every 2 weeks on an outpatient basis. Both patients had multiple liver metastases with high serum levels of AFP, and one demonstrated resistance to 5-fluorouracil. In both patients, liver metastases showed a dramatic complete response to chemotherapy, and the serum AFP levels returned to normal. No significant toxicities were observed. These preliminary results suggest that the present regimen may cause fewer side effects while retaining its synergistic antitumor activity. This regimen may therefore be worth trying as first-line chemotherapy for patients with metastatic AFP-producing gastric carcinoma.